1 Market Overview

• 1.1 Product Overview and Scope
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Market Analysis by Type
  • 1.3.1 Overview: Global Dapagliflozin and Metformin Extended-Release Tablets Consumption Value by Type: 2021 Versus 2025 Versus 2032
  • 1.3.2 10mg/1000mg
  • 1.3.3 5mg + 500mg
• 1.4 Market Analysis by Production Technology
  • 1.4.1 Overview: Global Dapagliflozin and Metformin Extended-Release Tablets Consumption Value by Production Technology: 2021 Versus 2025 Versus 2032
  • 1.4.2 Innovator
  • 1.4.3 Generic
• 1.5 Market Analysis by Dosage Form
  • 1.5.1 Overview: Global Dapagliflozin and Metformin Extended-Release Tablets Consumption Value by Dosage Form: 2021 Versus 2025 Versus 2032
  • 1.5.2 Extended-release tablet
  • 1.5.3 Conventional Tablet
• 1.6 Market Analysis by Application
  • 1.6.1 Overview: Global Dapagliflozin and Metformin Extended-Release Tablets Consumption Value by Application: 2021 Versus 2025 Versus 2032
  • 1.6.2 Type 2 Diabetes
  • 1.6.3 Weight Management
  • 1.6.4 Cardiovascular
  • 1.6.5 Others
• 1.7 Global Dapagliflozin and Metformin Extended-Release Tablets Market Size & Forecast
  • 1.7.1 Global Dapagliflozin and Metformin Extended-Release Tablets Consumption Value (2021 & 2025 & 2032)
  • 1.7.2 Global Dapagliflozin and Metformin Extended-Release Tablets Sales Quantity (2021-2032)
  • 1.7.3 Global Dapagliflozin and Metformin Extended-Release Tablets Average Price (2021-2032)

2 Manufacturers Profiles

• 2.1 AstraZeneca
  • 2.1.1 AstraZeneca Details
  • 2.1.2 AstraZeneca Major Business
  • 2.1.3 AstraZeneca Dapagliflozin and Metformin Extended-Release Tablets Product and Services
  • 2.1.4 AstraZeneca Dapagliflozin and Metformin Extended-Release Tablets Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.1.5 AstraZeneca Recent Developments/Updates
• 2.2 Merck
  • 2.2.1 Merck Details
  • 2.2.2 Merck Major Business
  • 2.2.3 Merck Dapagliflozin and Metformin Extended-Release Tablets Product and Services
  • 2.2.4 Merck Dapagliflozin and Metformin Extended-Release Tablets Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.2.5 Merck Recent Developments/Updates
• 2.3 Pfizer
  • 2.3.1 Pfizer Details
  • 2.3.2 Pfizer Major Business
  • 2.3.3 Pfizer Dapagliflozin and Metformin Extended-Release Tablets Product and Services
  • 2.3.4 Pfizer Dapagliflozin and Metformin Extended-Release Tablets Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.3.5 Pfizer Recent Developments/Updates

3 Competitive Environment: Dapagliflozin and Metformin Extended-Release Tablets by Manufacturer

• 3.1 Global Dapagliflozin and Metformin Extended-Release Tablets Sales Quantity by Manufacturer (2021-2026)
• 3.2 Global Dapagliflozin and Metformin Extended-Release Tablets Revenue by Manufacturer (2021-2026)
• 3.3 Global Dapagliflozin and Metformin Extended-Release Tablets Average Price by Manufacturer (2021-2026)
• 3.4 Market Share Analysis (2025)
  • 3.4.1 Producer Shipments of Dapagliflozin and Metformin Extended-Release Tablets by Manufacturer Revenue ($MM) and Market Share (%): 2025
  • 3.4.2 Top 3 Dapagliflozin and Metformin Extended-Release Tablets Manufacturer Market Share in 2025
  • 3.4.3 Top 6 Dapagliflozin and Metformin Extended-Release Tablets Manufacturer Market Share in 2025
• 3.5 Dapagliflozin and Metformin Extended-Release Tablets Market: Overall Company Footprint Analysis
  • 3.5.1 Dapagliflozin and Metformin Extended-Release Tablets Market: Region Footprint
  • 3.5.2 Dapagliflozin and Metformin Extended-Release Tablets Market: Company Product Type Footprint
  • 3.5.3 Dapagliflozin and Metformin Extended-Release Tablets Market: Company Product Application Footprint
• 3.6 New Market Entrants and Barriers to Market Entry
• 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

• 4.1 Global Dapagliflozin and Metformin Extended-Release Tablets Market Size by Region
  • 4.1.1 Global Dapagliflozin and Metformin Extended-Release Tablets Sales Quantity by Region (2021-2032)
  • 4.1.2 Global Dapagliflozin and Metformin Extended-Release Tablets Consumption Value by Region (2021-2032)
  • 4.1.3 Global Dapagliflozin and Metformin Extended-Release Tablets Average Price by Region (2021-2032)
• 4.2 North America Dapagliflozin and Metformin Extended-Release Tablets Consumption Value (2021-2032)
• 4.3 Europe Dapagliflozin and Metformin Extended-Release Tablets Consumption Value (2021-2032)
• 4.4 Asia-Pacific Dapagliflozin and Metformin Extended-Release Tablets Consumption Value (2021-2032)
• 4.5 South America Dapagliflozin and Metformin Extended-Release Tablets Consumption Value (2021-2032)
• 4.6 Middle East & Africa Dapagliflozin and Metformin Extended-Release Tablets Consumption Value (2021-2032)

5 Market Segment by Type

• 5.1 Global Dapagliflozin and Metformin Extended-Release Tablets Sales Quantity by Type (2021-2032)
• 5.2 Global Dapagliflozin and Metformin Extended-Release Tablets Consumption Value by Type (2021-2032)
• 5.3 Global Dapagliflozin and Metformin Extended-Release Tablets Average Price by Type (2021-2032)

6 Market Segment by Application

• 6.1 Global Dapagliflozin and Metformin Extended-Release Tablets Sales Quantity by Application (2021-2032)
• 6.2 Global Dapagliflozin and Metformin Extended-Release Tablets Consumption Value by Application (2021-2032)
• 6.3 Global Dapagliflozin and Metformin Extended-Release Tablets Average Price by Application (2021-2032)

7 North America

• 7.1 North America Dapagliflozin and Metformin Extended-Release Tablets Sales Quantity by Type (2021-2032)
• 7.2 North America Dapagliflozin and Metformin Extended-Release Tablets Sales Quantity by Application (2021-2032)
• 7.3 North America Dapagliflozin and Metformin Extended-Release Tablets Market Size by Country
  • 7.3.1 North America Dapagliflozin and Metformin Extended-Release Tablets Sales Quantity by Country (2021-2032)
  • 7.3.2 North America Dapagliflozin and Metformin Extended-Release Tablets Consumption Value by Country (2021-2032)
  • 7.3.3 United States Market Size and Forecast (2021-2032)
  • 7.3.4 Canada Market Size and Forecast (2021-2032)
  • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

• 8.1 Europe Dapagliflozin and Metformin Extended-Release Tablets Sales Quantity by Type (2021-2032)
• 8.2 Europe Dapagliflozin and Metformin Extended-Release Tablets Sales Quantity by Application (2021-2032)
• 8.3 Europe Dapagliflozin and Metformin Extended-Release Tablets Market Size by Country
  • 8.3.1 Europe Dapagliflozin and Metformin Extended-Release Tablets Sales Quantity by Country (2021-2032)
  • 8.3.2 Europe Dapagliflozin and Metformin Extended-Release Tablets Consumption Value by Country (2021-2032)
  • 8.3.3 Germany Market Size and Forecast (2021-2032)
  • 8.3.4 France Market Size and Forecast (2021-2032)
  • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
  • 8.3.6 Russia Market Size and Forecast (2021-2032)
  • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

• 9.1 Asia-Pacific Dapagliflozin and Metformin Extended-Release Tablets Sales Quantity by Type (2021-2032)
• 9.2 Asia-Pacific Dapagliflozin and Metformin Extended-Release Tablets Sales Quantity by Application (2021-2032)
• 9.3 Asia-Pacific Dapagliflozin and Metformin Extended-Release Tablets Market Size by Region
  • 9.3.1 Asia-Pacific Dapagliflozin and Metformin Extended-Release Tablets Sales Quantity by Region (2021-2032)
  • 9.3.2 Asia-Pacific Dapagliflozin and Metformin Extended-Release Tablets Consumption Value by Region (2021-2032)
  • 9.3.3 China Market Size and Forecast (2021-2032)
  • 9.3.4 Japan Market Size and Forecast (2021-2032)
  • 9.3.5 South Korea Market Size and Forecast (2021-2032)
  • 9.3.6 India Market Size and Forecast (2021-2032)
  • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
  • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

• 10.1 South America Dapagliflozin and Metformin Extended-Release Tablets Sales Quantity by Type (2021-2032)
• 10.2 South America Dapagliflozin and Metformin Extended-Release Tablets Sales Quantity by Application (2021-2032)
• 10.3 South America Dapagliflozin and Metformin Extended-Release Tablets Market Size by Country
  • 10.3.1 South America Dapagliflozin and Metformin Extended-Release Tablets Sales Quantity by Country (2021-2032)
  • 10.3.2 South America Dapagliflozin and Metformin Extended-Release Tablets Consumption Value by Country (2021-2032)
  • 10.3.3 Brazil Market Size and Forecast (2021-2032)
  • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

• 11.1 Middle East & Africa Dapagliflozin and Metformin Extended-Release Tablets Sales Quantity by Type (2021-2032)
• 11.2 Middle East & Africa Dapagliflozin and Metformin Extended-Release Tablets Sales Quantity by Application (2021-2032)
• 11.3 Middle East & Africa Dapagliflozin and Metformin Extended-Release Tablets Market Size by Country
  • 11.3.1 Middle East & Africa Dapagliflozin and Metformin Extended-Release Tablets Sales Quantity by Country (2021-2032)
  • 11.3.2 Middle East & Africa Dapagliflozin and Metformin Extended-Release Tablets Consumption Value by Country (2021-2032)
  • 11.3.3 Turkey Market Size and Forecast (2021-2032)
  • 11.3.4 Egypt Market Size and Forecast (2021-2032)
  • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
  • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

• 12.1 Dapagliflozin and Metformin Extended-Release Tablets Market Drivers
• 12.2 Dapagliflozin and Metformin Extended-Release Tablets Market Restraints
• 12.3 Dapagliflozin and Metformin Extended-Release Tablets Trends Analysis
• 12.4 Porters Five Forces Analysis
  • 12.4.1 Threat of New Entrants
  • 12.4.2 Bargaining Power of Suppliers
  • 12.4.3 Bargaining Power of Buyers
  • 12.4.4 Threat of Substitutes
  • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

• 13.1 Raw Material of Dapagliflozin and Metformin Extended-Release Tablets and Key Manufacturers
• 13.2 Manufacturing Costs Percentage of Dapagliflozin and Metformin Extended-Release Tablets
• 13.3 Dapagliflozin and Metformin Extended-Release Tablets Production Process
• 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

• 14.1 Sales Channel
  • 14.1.1 Direct to End-User
  • 14.1.2 Distributors
• 14.2 Dapagliflozin and Metformin Extended-Release Tablets Typical Distributors
• 14.3 Dapagliflozin and Metformin Extended-Release Tablets Typical Customers

15 Research Findings and Conclusion

16 Appendix

• 16.1 Methodology
• 16.2 Research Process and Data Source

According to our (Global Info Research) latest study, the global Dapagliflozin and Metformin Extended-Release Tablets market size was valued at US$ 529 million in 2025 and is forecast to a readjusted size of US$ 1681 million by 2032 with a CAGR of 14.8% during review period.
In 2025, global Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets production reached approximately 12.5 million units.Dapagliflozin and Metformin Extended-Release Tablets are a combination oral hypoglycemic drug primarily used to treat type 2 diabetes. This medication combines dapagliflozin (an SGLT-2 inhibitor) and metformin (a classic oral hypoglycemic drug), working synergistically. Dapagliflozin reduces blood glucose levels by inhibiting the kidney's reabsorption of glucose, while metformin helps control blood glucose by improving insulin sensitivity and reducing hepatic glucose production. The extended-release tablet formulation allows for the gradual release of the drug over time, minimizing side effects and enhancing patient adherence to the treatment. It is suitable for long-term blood glucose control in patients with type 2 diabetes.
Dapagliflozin and Metformin Extended-Release Tablets, as a novel combination hypoglycemic drug, demonstrate significant market potential in the treatment of type 2 diabetes due to its innovative combination therapy and extended-release technology. With the growing global prevalence of diabetes, especially in aging societies, the demand for diabetes medications continues to rise. Dapagliflozin helps patients effectively control blood glucose by inhibiting the SGLT-2 transporter, while metformin provides a dual glucose-lowering effect by improving insulin sensitivity and reducing hepatic glucose production.
The extended-release formulation of dapagliflozin and metformin offers better tolerance and fewer side effects, improving patient adherence, which is crucial for the long-term management of diabetes. Additionally, with the advancement of precision medicine, the demand for personalized treatments is increasing, and combination drugs like dapagliflozin and metformin extended-release tablets are better able to meet the diverse needs of patients.
This report is a detailed and comprehensive analysis for global Dapagliflozin and Metformin Extended-Release Tablets market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Dapagliflozin and Metformin Extended-Release Tablets market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Dapagliflozin and Metformin Extended-Release Tablets market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Dapagliflozin and Metformin Extended-Release Tablets market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Dapagliflozin and Metformin Extended-Release Tablets market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Dapagliflozin and Metformin Extended-Release Tablets
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Dapagliflozin and Metformin Extended-Release Tablets market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AstraZeneca, Merck, Pfizer, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Dapagliflozin and Metformin Extended-Release Tablets market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
10mg/1000mg
5mg + 500mg
Market segment by Production Technology
Innovator
Generic
Market segment by Dosage Form
Extended-release tablet
Conventional Tablet
Market segment by Application
Type 2 Diabetes
Weight Management
Cardiovascular
Others
Major players covered
AstraZeneca
Merck
Pfizer
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Dapagliflozin and Metformin Extended-Release Tablets product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Dapagliflozin and Metformin Extended-Release Tablets, with price, sales quantity, revenue, and global market share of Dapagliflozin and Metformin Extended-Release Tablets from 2021 to 2026.
Chapter 3, the Dapagliflozin and Metformin Extended-Release Tablets competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Dapagliflozin and Metformin Extended-Release Tablets breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Dapagliflozin and Metformin Extended-Release Tablets market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Dapagliflozin and Metformin Extended-Release Tablets.
Chapter 14 and 15, to describe Dapagliflozin and Metformin Extended-Release Tablets sales channel, distributors, customers, research findings and conclusion.